Post-Clearance: Your AI’s Real Regulatory Test Begins Now

Listen to this article · 7 min listen

Getting FDA clearance for an AI health tool is a major achievement, but it’s the starting gun, not the finish line. For any imaging and diagnostics vendor, what happens to your performance evidence after you get that clearance is everything. Your compliance infrastructure for post-market performance, the systems you have to prove the tool still works, is what determines your market viability and regulatory standing in the long run.

So, what happens to the evidence after a product is cleared? That’s the core question. Real-World Performance Monitoring is the main criterion, and the FDA’s Good Machine Learning Practice (GMLP) gives you the set of expectations for keeping a cleared model accountable as it inevitably changes. You have to think of post-clearance evidence as infrastructure. It’s not just paperwork. A smart buyer will ask if performance is being tracked against a written plan and whether your team actually adopted the GMLP expectations or just gave them a head nod.

The Continuing Obligation of Performance Evidence

An FDA clearance decision simply means an AI medical device met a specific set of pre-market requirements. But AI/ML models aren’t static, they can adapt and change, which requires ongoing vigilance. The FDA’s AI/ML Action Plan, which they kicked off in 2021, directly confronts this reality by outlining five pillars that include developing GMLP and monitoring real-world performance FDA AI/ML Action Plan details. This shows a static, one-time clearance is simply not enough for these dynamic tools. The FDA now expects companies to maintain a tailored regulatory framework, often using Predetermined Change Control Plans (PCCPs), to manage how these models evolve.

The high recall rates we’re seeing show exactly why strong post-market surveillance is needed. A JAMA Health Forum study from August 2025 found that 6% of FDA-cleared AI/ML medical devices ended up being recalled which is a much higher rate than for non-AI devices. That 6% isn’t just a number. It quantifies the real risk that comes from gaps in post-market oversight and points to more clinical uncertainty and regulatory crackdowns if performance isn’t continuously watched and managed JAMA study on AI/ML device recalls.

Real-World Performance Monitoring as a Criterion

Real-World Performance Monitoring (RWE) isn’t some optional best practice. It is a hard compliance criterion. It means you’re systematically collecting and analyzing performance data from your devices as they’re being used in actual clinics. This data can be pulled from electronic health records, patient registries, and even insurance claims. For an AI health tool, this kind of monitoring is the only way to detect algorithmic drift, what happens when your model’s performance degrades because real-world data no longer looks like the training data. Without it, a model cleared on historical data could become inaccurate or dangerous in today’s clinical setting.

The FDA’s focus on this is clear. Companies like Aidoc, Butterfly Network, and Tempus AI are all operating with these expectations hanging over them. Their post-market surveillance strategies, including the details of how they track performance against their written plans, have become auditable components of their entire regulatory posture. The question for compliance and quality leads has changed. It’s not just “was the product cleared?” It’s now “how is its ongoing performance being verified and documented?”

Good Machine Learning Practice: Beyond Acknowledgment

The FDA worked with organizations like the WHO and UK MHRA to publish 10 guiding principles for Good Machine Learning Practice (GMLP) FDA GMLP guiding principles. These principles are there to ensure AI/ML medical devices are deployed safely and effectively. They cover the entire lifecycle, from data management and model development to performance evaluation and transparency. For companies like Aidoc, Tempus AI, and Butterfly Network, adopting these principles isn’t optional. It’s the foundation of their ongoing regulatory accountability.

There’s a world of difference between just acknowledging GMLP principles and truly adopting them. Adoption means you’ve integrated these practices deep into your core quality management system (QMS) and daily operations. Do you have defined processes for data governance, model retraining, bias mitigation, and continuous performance assessment? Compliance and quality leads must evaluate whether a vendor’s GMLP framework is actually embedded in their architecture or if it’s just a document living in a separate folder somewhere.

Infrastructure Questions for Buyers and Regulators

For imaging and diagnostics vendors looking at AI health tools, the quality of the post-clearance evidence is a checkable piece of infrastructure. This gets you past simple vendor claims and into verifiable systems and processes. When you’re evaluating AI solutions, these are the key questions to ask:

  • Can the vendor show you a documented plan for Real-World Performance Monitoring and provide evidence they’re actually following it?
  • How does the vendor apply FDA Good Machine Learning Practice principles in their product lifecycle, from development all the way through post-market surveillance? Can they point to it?
  • What happens when the algorithm starts to drift or degrade in the field? Is there a clear, documented process for detecting and fixing it?
  • What specific mechanisms are they using to collect and analyze real-world data, and how is that data integrated back into model refinement or regulatory submissions?
  • Can the vendor show you evidence of a solid Quality Management System (QMS), like an ISO 13485 certification, that explicitly covers their AI/ML development and maintenance processes?

Companies like Aidoc, Butterfly Network, and Tempus AI are increasingly expected to have transparent answers here. The FDA’s own regulatory risk scorecard, which assesses SaMD readiness on things like GMLP compliance and post-market surveillance, shows how important these infrastructural elements are. With 335 AI/ML devices cleared by the FDA in 2025 alone (and 96% of them using the 510(k) pathway), the high throughput of initial clearances only increases the need for strong post-market oversight FDA AI-Enabled Medical Device List.

In the end, a clearance decision is just the beginning. The real measure of an AI health tool’s regulatory maturity and its long-term viability is the strength of its post-clearance evidence infrastructure. This infrastructure is the operational backbone that ensures the tool remains safe, effective, and compliant in a field that’s always changing.

Frequently Asked Questions

What is the primary regulatory focus for AI health tools after FDA clearance?

After FDA clearance, the primary regulatory focus shifts to post-market performance and ongoing vigilance. This includes real-world performance monitoring and adherence to FDA Good Machine Learning Practice (GMLP). A static clearance is insufficient for dynamic AI tools, necessitating a tailored regulatory framework.

Why is Real-World Performance Monitoring crucial for AI/ML medical devices?

Real-World Performance Monitoring is crucial because AI/ML models can adapt and change over time, leading to algorithmic drift where performance degrades. Systematic collection and analysis of performance data from devices in actual clinical use helps detect these changes. This ensures the AI model remains accurate and effective in current clinical practice.

What does ‘adopting’ Good Machine Learning Practice (GMLP) entail, beyond mere acknowledgment?

Adopting GMLP means integrating its principles into the core quality management system (QMS) and operational workflows. This includes defined processes for data governance, model retraining, bias mitigation, and continuous performance assessment. It signifies a deeper embedding of these practices into the vendor’s architecture, not just a separate set of guidelines.

What evidence should vendors provide regarding their post-clearance compliance infrastructure?

Vendors should provide evidence of a documented plan for Real-World Performance Monitoring and its consistent execution. They should also demonstrate adherence to FDA GMLP principles throughout their product lifecycle. This includes clear processes for detecting and addressing algorithmic drift and robust QMS coverage for AI/ML development and maintenance.

Editorial Team

The Editorial Team at Regulated AI Health is a group of writers and editors who cover health, workplace wellness, and everyday care. They research each story and publish under a shared desk byline — experts in their fields, working as one team.